First-In-Human Study for Novel Trispecific Antibody | Rakesh Popat, BSc, MBBS, MRCP, PhD | скачать в хорошем качестве

First-In-Human Study for Novel Trispecific Antibody | Rakesh Popat, BSc, MBBS, MRCP, PhD |

In a groundbreaking first-in-human clinical trial, Janssen (a Johnson & Johnson company) named JNJ-79635322 has introduced a novel trispecific antibody designed to treat multiple myeloma. This innovative therapy goes beyond traditional bispecific antibodies by targeting three key components: two distinct markers on myeloma cells (BCMA and GPRC5D) and CD3 on T-cells. The goal? To activate the immune system more precisely and powerfully against the cancer. Encouraging Phase 1 data support advancement into Phase 2/3 trials in this patient population. These results were first presented at ASCO 2025 and recognized as a top abstract at EHA 2025. Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer! Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_so... Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.